Legal Basis:
Directive 2014/24/EU
Section I: Contracting authority
I.1)Name and addressesOfficial name: INSTITUT JULES BORDET (IJB)
Postal address: RUE HEGER BORDET 1
Town: Brussels
NUTS code:
BE100 Arr. de Bruxelles-Capitale / Arr. Brussel-HoofdstadPostal code: 1000
Country: Belgium
E-mail:
philippe.aftimos@bordet.beInternet address(es): Main address:
https://oncngs.eu/Address of the buyer profile:
https://www.bordet.be I.2)Information about joint procurementThe contract involves joint procurement
In the case of joint procurement involving different countries, state applicable national procurement law:
Ce marché précommercial (PCP) est réalisé par SCIENSANO, qui a été nommé acheteur principal. Le droit national applicable aux marchés publics est le droit belge.
I.3)CommunicationAdditional information can be obtained from the abovementioned address
I.4)Type of the contracting authorityBody governed by public law
Section II: Object
II.1)Scope of the procurement
II.1.1)Title:
Achat précommercial pour l’achat de services de R&D pour le développement d’une solution d’analyse dans des biopsies liquides de tumeurs solides fondées sur la technologie NGS
Reference number: Sciensano-000-ONCNGS (1)-F02_0
II.1.2)Main CPV code73100000 Research and experimental development services
II.1.3)Type of contractServices
II.1.4)Short description:
The mutational profiling of tumours requires complex, invasive and expensive procedures but is rapidly becoming essential for an efficient and adequate provision of care for cancer patients, especially when the disease has already advanced to metastatic conditions, in which the identification of tumour biomarkers is relevant to identify the best targeted therapy. However, access to tumour tissue remains a limiting factor for the assessment of biomarkers, and mounting evidence suggests that may even be inadequate to capture the clonal heterogeneity that often drives resistance. The assessment of circulating biomarkers is rapidly gaining ground as a non-invasive alternative that offers the additional possibility of serially monitoring disease evolution and the potential to obtain a more comprehensive picture of the tumour genetic heterogeneity. However, the current development trajectory for large cfDNA tests is heavily reliant on costly, high throughput centralized sequencing and appears ill-suited for European common practice.
The oncNGS PCP aims at developing an integrated solution for predictive, prognostic and diagnostic analysis in liquid biopsies of solid tumours (including appropriate haematological indications) based on NGS technology.
This PCP tackles the common global unmet need in oncology to profile multiple tumours at the molecular level in the broadest possible way, promoting an economically sustainable and de-centralised model that allows a secure and transparent access to sensitive data. All partners in this consortium do agree that they face a common challenge in providing ‘the best NGS tests, for all solid and lymphoid tumours, forever’. They agree that a commonly identified procurement meets a need that is shared by all procurers in the Buyers Group of the project that forms the object of the here proposed PCP procurement ‘oncNGS’.
More information regarding the goal of the oncNGS PCP and the PCP Challenge can be found in Annex 2 – Challenge Brief, as well as the technical and functional specifications.
II.1.5)Estimated total valueValue excluding VAT: 7 073 554.00 EUR
II.1.6)Information about lotsThis contract is divided into lots: no
II.2)Description
II.2.2)Additional CPV code(s)33000000 Medical equipments, pharmaceuticals and personal care products
38000000 Laboratory, optical and precision equipments (excl. glasses)
48180000 Medical software package
73100000 Research and experimental development services
73300000 Design and execution of research and development
73000000 Research and development services and related consultancy services
72212460 Analytical, scientific, mathematical or forecasting software development services
72212461 Analytical or scientific software development services
72000000 IT services: consulting, software development, Internet and support
71900000 Laboratory services
II.2.3)Place of performanceNUTS code: BE Belgique / België
Main site or place of performance:
La R&D sera principalement réalisée en Europe.
Les tests devraient avoir lieu à Bruxelles (Belgique), Paris, Lyon (France), Berlin, Munich (Allemagne), Barcelone (Espagne), Milan, Rome (Italie)
II.2.4)Description of the procurement:
The mutational profiling of tumours requires complex, invasive and expensive procedures but is rapidly becoming essential for an efficient and adequate provision of care for cancer patients, especially when the disease has already advanced to metastatic conditions, in which the identification of tumour biomarkers is relevant to identify the best targeted therapy. However, access to tumour tissue remains a limiting factor for the assessment of biomarkers, and mounting evidence suggests that may even be inadequate to capture the clonal heterogeneity that often drives resistance. The assessment of circulating biomarkers is rapidly gaining ground as a non-invasive alternative that offers the additional possibility of serially monitoring disease evolution and the potential to obtain a more comprehensive picture of the tumour genetic heterogeneity. However, the current development trajectory for large cfDNA tests is heavily reliant on costly, high throughput centralized sequencing and appears ill-suited for European common practice.
The oncNGS PCP aims at developing an integrated solution for predictive, prognostic and diagnostic analysis in liquid biopsies of solid tumours (including appropriate haematological indications) based on NGS technology.
This PCP tackles the common global unmet need in oncology to profile multiple tumours at the molecular level in the broadest possible way, promoting an economically sustainable and de-centralised model that allows a secure and transparent access to sensitive data. All partners in this consortium do agree that they face a common challenge in providing ‘the best NGS tests, for all solid and lymphoid tumours, forever’. They agree that a commonly identified procurement meets a need that is shared by all procurers in the Buyers Group of the project that forms the object of the here proposed PCP procurement ‘oncNGS’.
More information regarding the goal of the oncNGS PCP and the PCP Challenge can be found in Annex 2 – Challenge Brief, as well as the technical and functional specifications.
II.2.5)Award criteriaPrice is not the only award criterion and all criteria are stated only in the procurement documents
II.2.6)Estimated value
II.2.7)Duration of the contract, framework agreement or dynamic purchasing systemDuration in months: 38
This contract is subject to renewal: no
II.2.10)Information about variantsVariants will be accepted: no
II.2.11)Information about optionsOptions: no
II.2.13)Information about European Union fundsThe procurement is related to a project and/or programme financed by European Union funds: yes
Identification of the project:
This project has received funding from the European Union’s Horizon 2020 research and innovation programme under grant agreement n° 874467
II.2.14)Additional information
Voir le document PCP et autres documents du marché joints
Section III: Legal, economic, financial and technical information
III.1)Conditions for participation
III.1.3)Technical and professional abilityMinimum level(s) of standards possibly required:
Classe: N/A, Catégorie: N/A
Section IV: Procedure
IV.1)Description
IV.1.1)Type of procedureOpen procedure
IV.1.3)Information about a framework agreement or a dynamic purchasing system
IV.1.8)Information about the Government Procurement Agreement (GPA)The procurement is covered by the Government Procurement Agreement: no
IV.2)Administrative information
IV.2.1)Previous publication concerning this procedure IV.2.2)Time limit for receipt of tenders or requests to participateDate: 02/02/2022
Local time: 14:00
IV.2.3)Estimated date of dispatch of invitations to tender or to participate to selected candidates
IV.2.4)Languages in which tenders or requests to participate may be submitted:English, French, Dutch
IV.2.7)Conditions for opening of tendersDate: 02/02/2022
Local time: 14:00
Section VI: Complementary information
VI.1)Information about recurrenceThis is a recurrent procurement: no
VI.3)Additional information:
VI.4)Procedures for review
VI.4.1)Review bodyOfficial name: Conseil d'Etat
Town: Bruxelles
Postal code: 1040
Country: Belgium
VI.5)Date of dispatch of this notice:02/12/2021